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Abstract
Background: Patients with schizophrenia are at high risk of developing metabolic abnormalities.
Method: A prospective study focusing on metabolic disturbances in patients with schizophrenia,
including an oral glucose tolerance test, is currently ongoing at our University Hospital and affiliate
services. The prevalence of metabolic abnormalities at baseline was assessed in a cohort of 415
patients with schizophrenia. The sample was divided into 4 groups according to duration of illness:
first-episode patients (<1.5 years), recent-onset patients (between 1.5 and 10 years), subchronic
patients (between 10 and 20 years) and chronic patients (>20 years).
Results: Metabolic abnormalities were already present in first-episode patients, and considerably
increased with increasing duration of illness. When compared to the general population matched
for age and gender, much higher rates of the metabolic syndrome (MetS) and diabetes were
observed for patients with schizophrenia. For MetS, the increase over time was similar to that of
the general population. In contrast, the difference in the prevalence of diabetes in patients with
schizophrenia and the general population dramatically and linearly increased from 1.6% in the 15–
25 age-band to 19.2% in the 55–65 age-band.
Conclusion: Thus, the current data suggest that on the one hand metabolic abnormalities are an
inherent part of schizophrenic illness, as they are already present in first-episode patients. On the
other hand, however, our results suggest a direct effect of the illness and/or antipsychotic
medication on their occurence. The data underscore the need for screening for metabolic
abnormalities in patients diagnosed with schizophrenia, already starting from the onset of the
illness.
Published: 27 June 2006
Clinical Practice and Epidemiology in Mental Health 2006, 2:14 doi:10.1186/1745-0179-2-
14
Received: 30 April 2006
Accepted: 27 June 2006
This article is available from: http://www.cpementalhealth.com/content/2/1/14
© 2006 De Hert et al; licensee BioMed Central Ltd.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.Clinical Practice and Epidemiology in Mental Health 2006, 2:14 http://www.cpementalhealth.com/content/2/1/14
Page 2 of 10
(page number not for citation purposes)
1. Background
Metabolic abnormalities have consistently been identified
as a part of schizophrenic illness [1-4], but with the intro-
duction of second generation antipsychotics and their
possible association with metabolic abnormalities [5-7],
the interest in this topic has been renewed.
Many studies have since then provided convincing evi-
dence for a high risk of diabetes and other glucose abnor-
malities [5,8-12], the metabolic syndrome[13,14], and
mortality due to elevated cardiovascular risk in patients
with schizophrenia [15-18].
These metabolic abnormalities are of major clinical con-
cern, not only because of their direct, somatic effects on
morbidity and mortality, but also because of their associ-
ation with psychiatric outcome, such as a higher preva-
lence of psychotic and depressive symptoms[19], a lower
functional outcome [20], a worse percieved physical
health [19] and lower adherence to medication [21].
The reasons that underlie the high prevalence of these
metabolic abnormalities are much debated, especially
when considering the possible role of second-generation,
'atypical' antipsychotics in the occurence of these abnor-
malities. On the one hand, many studies have suggested a
role of (certain) atypical antipsychotics in the occurrence
of metabolic abnormalities, both case reports [22-26],
cross-sectional or retrospective studies [27,28] as prospec-
tive studies [29,30]. On the other hand, other studies have
provided evidence for an increased prevalence of central
obesity [31] and glucose abnormalities such as impaired
fasting glucose and insulin resistance [32] in drug-naïve
first-episode patients, suggesting that metabolic abnor-
malities are an inherent part of schizophrenic illness.
Most probably, these two views represent a polarisation of
clinical reality, as medical factors (weight, age,...), psycho-
social factors (environmental stress, exercise, dietary hab-
its,...), genetic factors (family history of diabetes, possible
genetic overlap with psychiatric illness) and pharmaco-
logical factors (weight gain, medication-induced lipid and
glucose abnormalities) are likely to interact in their influ-
ence on the occurrence of metabolic abnormalities, mak-
ing it difficult to disentangle the influence of each
individual risk factor.
Next to the interrelationship of the individual risk factors,
the lack of insight into the development and course of
these metabolic abnormalities makes an evaluation of the
best possible strategy to assess and treat these abnormali-
ties difficult. If metabolic abnormalities are already
present in the first illness episode of psychotic patients
and are an inherent part of psychiatric illness, would it be
useful then to invest in prevention strategies? On the
other hand, if metabolic abnormalities are caused by an
interplay of many risk factors, could early detection and
treatment of these risk factors result in a reduction of the
prevalence of these metabolic abnormalities, and thus in
a reduction of the excess mortality in patients with schiz-
ophrenia?
To address these issues, the current study aimed to gather
some insight into the development and course of meta-
bolic abnormalities in schizophrenia, by assessing the
presence of metabolic abnormalities in 4 cohorts of
patients with schizophrenia: a cohort of first-episode
patients with a duration of illness (DOI) of less than 1.5
years, a cohort of recent-onset patients with a DOI of 1.5
to 10 years, a cohort of subchronic patients with a DOI of
10 to 20 years and a cohort of chronic patients with a DOI
of more than 20 years. It was hypothesized that metabolic
abnormalities would already be present in first-episode
patients, but that their prevalence would increase with
DOI, in a rate that would be higher than that of the gen-
eral population matched for age and gender.
2. Methods
All consecutive patients with a DSM-IV diagnosis of schiz-
ophrenia (SCH) or schizoaffective (SA), both out-
(26.3%) or inpatients, of the university psychiatric hospi-
tal St. Jozef (Kortenberg, Belgium) and its affiliate services,
were asked to participate in an extensive screening and
prospective follow-up study of metabolic parameters. The
prospective inclusions started in November 2003. At base-
line, patients received a full fasting laboratory screening
(including a full lipid profile and measurement of gly-
cated haemoglobin (HbA1c)), clinical measurements and
an ECG. A 75 gr glucose load Oral Glucose Tolerance Test
(OGTT) was performed in all patients. Patients were initi-
ated on an overnight fast and were monitored during the
OGTT. Insulin resistance was measured using fasting glu-
cose and insulin concentrations with the HOMA method.
All laboratory analyses were performed in the same labo-
ratory.
The sample was divided into 4 groups according to dura-
tion of illness: first-episode patients (DOI<1.5 years),
recent-onset patients (DOI<10 years), subchronic patients
(DOI between 10 and 20 years) and chronic patients
(DOI >20 years).
The presence of the MetS was assessed using the ATP-III
criteria [33], the adapted ATP-III criteria (fasting glucose ≥
100 mg/dl instead of 110 mg/dl) [34] and the recent IDF
criteria (Table 1) [35]. For the diagnosis of diabetes and
prediabetic abnormalities, the criteria of The American
Diabetes Association were used (Impaired fasting glucose
(IFG ≥ 100 mg/dl and Impaired Glucose Tolerance (IGT),
glucose ≥ 140 mg/dl at 2 hours in the OGTT) [36].Clinical Practice and Epidemiology in Mental Health 2006, 2:14 http://www.cpementalhealth.com/content/2/1/14
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Descriptive statistics were computed for the basic demo-
graphic and clinical variables as well as for the variables
relevant for the evaluation of metabolic abnormalities.
The influence of the presence/absence of the metabolic
syndrome and the presence/absence of glucose abnormal-
ities on continuous variables was assessed by means of an
independent samples t-test. The association between cate-
gorical variables was evaluated by a chi-square test.
In a second approach, in order to allow a comparison with
the general population, the sample was dived into ten-
year age-bands (15–25; 25–35; 35–45; 45–55 and 55–65
year old patients). The population data for the compari-
son for MetS came from the Asklepios Study [38]. In this
study cardiovascular risk factors were evaluated by a pri-
mary care physician in 2,524 healthy subjects between 35
and 55. The data for the comparison of the prevalence of
diabetes was obtained from an online Belgian Govern-
ment report [39]. This report is based on all epidemiolog-
ical data on diabetes available in Belgium and an
evaluation of sales of antidiabetic medication, all ages,
and a survey of pharmacies. A weighted mean was calcu-
lated for the general population age-bands to control for
gender differences (percentage of male patients in the cur-
rent study sample times prevalence of diabetes/MetS for
male subjects from the general population, plus percent-
age of female patients in the current study sample times
prevalence of diabetes/MetS for female subjects from the
general population). This weighted mean for the general
population was then compared to the mean of the study
sample per age band.
The study was approved by an ethical committee and all
patients gave written informed consent.
3. Results
3.1. Subjects
The mean age of the patients was 37.7 years (std 11.3) and
the mean duration of illness was 10.8 years (std 10.2). Of
all patients, 67.2% of patients were male; 99% were white
and Belgian natives. The studied population consisted of
415 patients with schizophrenia: 100 first-episode
patients (24.1%), 130 recent-onset patients (31.3%), 106
subchronic patients (25.5%) and 79 chronic patients
(19.0%). The demographic characteristics of the different
cohorts are shown in Table 2.
On average, patients took 3.2 (std 2.0) different medica-
tions. Antipsychotics were combined with anticholiner-
gics (16%), antidepressants (38%), benzodiazepines
(36%), mood stabilisers (21%) and somatic medication
(41%) (Table 3). Regarding somatic medication, 0.7% (3
patients) were being treated with metformin, 1.7% of
patients took a statin (7 patients) and 10.1% (42 patients)
took antihypertensive medication. 68% of all patients
were smokers, with no significant differences between
groups.
All but 2 patients were treated with antipsychotic medica-
tion at the time of assessment. First-generation antipsy-
chotics were used by 19.3% (n = 80) of patients, second-
generation antipsychotics by 91.1% (n = 378). The major-
ity of patients were treated with one antipsychotic (n =
349, or 84.1%); 90.0% of this group received a second-
generation antipsychotic, 10.0% a first-generation antip-
sychotic. Patients in the first-episode group were more
likely to receive second-generation antipsychotics, to take
a smaller number of different medications and to be on
monotherapy (Table 3).
3.2. Metabolic abnormalities according to duration of 
illness
First-episode patients had a normal BMI and BMI segmen-
tation (normal, overweight and obese). With increasing
DOI, weight also significantly increased. Similarly, there
was a significant increase in waist circumference (Tables 2
and 4). In all groups, there was a high prevalence of family
history of both metabolic (diabetes and lipid abnormali-
ties) as well as cardio-vascular disorders.
MetS was prevalent in all groups but significantly
increased with increasing DOI, as did the individual crite-
Table 1: Definitions of the metabolic syndrome.
ATP III* ATP III A* IDF**
Criteria:
Waist (cm) M >102, F >88 M >102, F >88 M ≥94, F ≥80 Obligatory criterion
BP*** ≥ 130/85 ≥ 130/85 ≥ 130/85
HDL (mg/dl) M <40, F <50 M <40, F <50 M <40, F <50
TG (≥ 150 mg/dl) ≥ 150 ≥ 150 ≥ 150
Glucose (mg/dl)**** ≥ 110 ≥ 100 ≥ 100
*MetS if 3 of 5 criteria are met.
**MetS if additional 2 criteria are met (waist is obligatory).
***Or if treated with antihypertensive medication.
****Or if treated with insulin or hypoglycaemic medication.Clinical Practice and Epidemiology in Mental Health 2006, 2:14 http://www.cpementalhealth.com/content/2/1/14
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ria, except for low HDL (Table 4 and Figure 2). The fre-
quency of elevated waist and glucose abnormalities was
more than doubled in patients with a duration of illness
of more than 10 years, when compared to first-episode
patients. Female compared to male patients were signifi-
cantly more often overweight or obese and more fre-
quently met the waist circumference criterium, according
to both ATP III and IDF criteria (df 1, χ2 = 30.6 and χ2 =
16.36, p < .0.0001).
In the total sample, 6.3% (n = 26) met criteria for diabe-
tes, another 23.4% (n = 97) had prediabetic abnormali-
ties, defined as impaired fasting glucose (IFG; fasting
glucose >125 mg/dl) and/or impaired glucose tolerance
(IGT; glucose ≥ 200 mg/dl at 120 minutes in the OGTT).
Of the patients meeting criteria for diabetes, 12 (46.2%)
met criteria with fasting values, 14 (53.8%) met criteria at
120 min in the OGTT and 4 (15.4%) met criteria both
fasting and at 120 min in the OGTT. This means that
when the current sample would have only been screened
with a fasting glucose assessment, as suggested by the
American Psychiatric Association/American Diabetes
Association 37, only 12 of the 26 diabetes cases (46.2%)
would have been identified. The prevalence of glucose
abnormalities differed significantly between the different
patient cohorts. The prevalence of diabetes increased from
3% in the first-episode and recent-onset group to 16.5%
in the chronic group (Table 5 and Figure 2.). The mean
values of parameters evaluated in the OGTT did not differ
significantly between groups. Diabetes and glucose abnor-
malities were more frequent in patients treated with cloz-
apine (df 10, χ2 = 29.17, p < .0012). The distribution of
glucose abnormalities over antipsychotic treatment
regimes is shown in table 6.
As expected, the prevalence of the metabolic syndrome,
regardless of the definition used, was significantly higher
in diabetic subjects (ATP-III 76.7%, ATP-III A 80.0%, IDF
80.0%) compared to patients with prediabetic abnormal-
ities (ATP-III 35.8%, ATP-III A 49.5%, IDF 54.1%) and
patients without glucose abnormalities (ATP-III 17.5%,
ATP-III A 17.7%, IDF 21.9%). Patients with MetS were
more likely to meet criteria for diabetes or prediabetic
abnormalities in all definitions of the MetS applied.
All parameters evaluated in the OGTT (glucose and insu-
lin values fasting, at 30 minutes, at 60 minutes and 120
minutes) as well as HOMA-IR and glycated haemoglobin
Table 2: Clinical and demographic data.
FE <10 yr 10 to 20 yr >20 yr p
Age 25.7 (± 8.2) 29.0 (± 7.5) 39.0 (± 6.1) 49.8 (± 5.8) 0.0001
Sex ns
Female 26% (26) 33.1% (43) 40.0% (36) 39.2% (26)
Male 74% (74) 66.9% (87) 66.0% (70) 60.8% (74)
GAF 58.4 (± 10.8) 61.9 (± 7.5) 61.7 (± 9.0) 59.7 (± 8.9)
Age first admission 25.2 (± 8.2) 23.8 (± 7.1) 24.2 (± 5.7) 22.2 (± 4.1) 0.0277
N admissions 1.6 (± 1.2) 3.9 (± 2.2) 6.8 (± 4.0) 9.0 (± 6.1) 0.0001
Duration illness 0.5 (± 0.4) 5.2 (± 2.4) 14.8 (± 2.8) 27.6 (± 5.7) 0.0001
N pills 2.1 (± 1.0) 2.8 (± 1.4) 3.8 (± 2.4) 4.2 (± 2.2) 0.0001
BMI 23.7 (± 1.3) 25.9 (± 5.2) 27.2 (± 5.3) 26.6 (± 5.0) 0.0001
BMI segmentation 0.0001
Normal 68% (68) 44.6% (58) 38.7% (41) 36.7% (29)
Overweight 23% (23) 40.0% (52) 32.1% (34) 41.8% (33)
Obese 9% (9) 15.4% (20) 29.2% (31) 21.5% (20)
Living situation 0.0001
Sheltered housing 1% (1) 11.5% (15) 20.8% (22) 24.0% (19)
With family 48% (48) 32.3% (42) 14.1% (15) 12.7% (10)
Partner 14% (14) 7.7% ()10 7.6% (8) 15.2% (12)
Alone 31% (31) 26.9% (35) 26.4% (28) 17.7% (14)
Residential facility 6% (6) 21.6% (28) 31.1% (33) 30.4% (24)
Occupation 0.0001
Work 11% (11) 3.0% (4) 6.6% (7) 7.6% (6)
Sheltered work 0% (0) 0.8% (1) 4.7% ()5 1.3% (1)
Study/training 25% (25) 15.4% (20) 10.4% (11) 1.3% (1)
None 64% (64) 80.8% (105) 78.3% (83) 89.9% (71)
Family history CVD 45% (45) 42.3% (55) 51.8% (55) 53.2% (45) ns
Family history 
Diabetes
32% (32) 23.1% (30) 35.8% (38) 36.7% (29) ns
Family history lipid 
disorder
34% (34) 36.1% (47) 36.8% (39) 30.4% (24) nsClinical Practice and Epidemiology in Mental Health 2006, 2:14 http://www.cpementalhealth.com/content/2/1/14
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A1c were significantly different between patients with or
without the metabolic syndrome regardless of the defini-
tion (p < .0001), with higher values in patients with MetS.
Similar highly significant differences were found on all
fasting serum lipid values and calculated lipid risk factors
for cardiovascular disease (cholesterol, triglycerides, HDL,
LDL, CHOL/HDL and LDL/HDL) (p < .0001).
Table 3: Medication in different groups.
FE <10 yr 10 to 20 yr >20 yr p
Anticholinergic 8% (8) 13.1% (17) 16.0% (17) 31.5% (25) 0.0002
Benzodiazepine 36% (36) 23.8% (31) 44.4% (46) 44.3% (35) 0.0003
Antidepressant 23% (23) 42.3% (55) 44.3% (47) 43.0% (34) 0.0043
Mood stabiliser 9% (9) 20.8% (27) 30.2% (72) 25.3% (20) 0.0019
Antipsychotic 0.0001
Only first generation 3 %(3) 4.6 %(6) 9.5% (10) 20.5% (16)
Only second 
generation
94% (94) 87.7% (113) 74.5% (79) 60.3% (47)
Combination 3% (3) 7.6% (10) 16.0% (17) 19.2% (15)
Second generation AP 97% (97) 94.6% (123) 90.5% (96) 78.5% (62)
Second generation (N 
= 400 prescriptions)
0.0001
Amisulpride (n = 32) 5% (5) 5.8% (6) 16.0% (17) 5.9% (4)
Aripiprazole (n = 4) 3% (3) 0.7% (1) 0% (0) 0% (0)
Clozapine (n = 74) 3% (3) 15.5% (20) 29.1% (30) 30.9% (21)
Risperidone (n = 98) 32% (32) 20.2% (26) 23.3% (24) 23.5% (16)
Quetiapine (n = 53) 10% (10) 10.7% (25) 10.7% (11) 10.3% (7)
Olanzapine (n = 139) 47% (47) 31.1% (32) 31.1% (32) 29.4% (20)
Table 4: Metabolic syndrome and criteria prevalence.
FE <10 yr 10 to 20 yr >20 yr p
MS ATP-III 17% (17) 21.5% (28) 34.9% (37) 36.7% (29) 0.0026
Criteria:
Waist (M>102, F>88) 18% (18) 32.3% (42) 45.3% (48) 44.3% (42) 0.0001
BP (≥ 130/85) 43% (43) 34.6% (45) 57.5% (61) 64.7% (51) 0.0001
HDL (M<40 mg/dl, 
F<50 mg/dl)
26% (26) 27.7% (36) 31.1% (33) 31.6% (26) ns
TG (≥ 150 mg/dl) 33% (33) 36.1% (47) 50.9% (54) 46.8% (37) 0.0252
Glucose (≥ 110 mg/dl) 3% (3) 2.3% (3) 11.3% (12) 20.2% (16) 0.0001
MS ATP-III A (AHA) 18% (18) 24.6% (32) 39.6% (42) 44.3% (35) 0.0001
Criteria:
Waist (M>102, F>88) 18% (18) 32.3% (42) 45.3% (48) 44.3% (42) 0.0001
BP (≥ 130/85) 43% (43) 34.6% (45) 57.5% (61) 64.7% (51) 0.0001
HDL (M<40 mg/dl, 
F<50 mg/dl)
26% (26) 27.7% (36) 31.1% (33) 31.6% (26) ns
TG (≥ 150 mg/dl) 33% (33) 36.1% (47) 50.9% (54) 46.8% (37) 0.0252
Glucose(≥ 100 mg/dl) 8% (8) 16.9% (22) 27.4% (29) 40.5% (32) 0.0001
MS IDF 17% (17) 28.5% (37) 42.4% (45) 49.4% (39) 0.0001
Criteria:
Waist (M ≥ 94, F ≥ 80) 38% (38) 55.4% (72) 73.6% (78) 70.9% (56) 0.0001
BP (≥ 130/85) 43% (43) 34.6% (45) 57.5% (61) 64.7% (51) 0.0001
HDL (M<40 mg/dl, 
F<50 mg/dl)
26% (26) 27.7% (36) 31.1% (33) 31.6% (26) ns
TG (≥ 150 mg/dl) 33% (33) 36.1% (47) 50.9% (54) 46.8% (37) 0.0252
Glucose (≥ 100 mg/dl) 8% (8) 16.9% (22) 27.4% (29) 40.5% (32) 0.0001Clinical Practice and Epidemiology in Mental Health 2006, 2:14 http://www.cpementalhealth.com/content/2/1/14
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The mean lipid values were lower in the first-episode
group, although not statistically significant, in contrast to
the frequency of abnormal lipid values that differed sig-
nificantly for total cholesterol, triglycerides, LDL, CHOL/
HDL and LDL/HDL (Table 7).
3.3. Comparison to the general population
The division of the study sample into age-bands resulted
in a group of 98 patients in the 15–25 age-band, 127 in
the 25–35 age-band, 99 in the 35–45 age-band, 71 in the
45–55 age-band and 20 in the oldest age-band (55–65).
Recent data on the prevalence of MetS according to ATP III
and IDF criteria in the population were available for the
age-bands 35–45 and 45–55 years old [38]. When com-
pared to the calculated weighted mean prevalence for the
general population, the prevalence of MetS was consider-
ably higher in patients. The increase with age of the prev-
alence of MetS was similar in patients and the general
population (Figure 3).
For diabetes, data were available on the prevalence for all
the age-bands that were investigated in the present study
[39]. In the age-band 15–25, a five times higher preva-
lence of diabetes was found when compared to the gen-
eral population. With increasing age, the absolute
difference between patients and the general population
dramatically and linearly increased from 1.6% in the 15–
25 age-band to 19.2% in the oldest age-band (Figure 4).
The prevalence of diabetes per age-band, however, was 4
to 5 times higher in patients (15–25: 5.0; 25–35: 3.6; 35–
45: 5.5; 45–55: 5.3 and 55–65: 4.3).
4. Discussion
4.1. Findings
The current study confirms the high prevalence of meta-
bolic abnormalities in patients diagnosed with schizo-
phrenia. In line with our hypothesis, metabolic
abnormalities were already present in first-episode
patients, but their prevalence considerably increased with
increasing duration of illness. More specifically, the rise in
the prevalence of metabolic abnormalities was most out-
spoken after an illness duration of ten or more years.
When compared to the general population matched for
age and gender, higher rates of the MetS and diabetes were
observed for patients with schizophrenia. For the MetS,
the increase of the prevalence was similar to that of the
general population. In contrast, the difference in the prev-
alence of diabetes in patients with schizophrenia and the
general population dramatically and linearly increased
Prevalence of the metabolic syndrome per age-band in  patients with schizophrenia compared to the general popula- tion according to ATP-III and IDF criteria Figure 3
Prevalence of the metabolic syndrome per age-band in 
patients with schizophrenia compared to the general popula-
tion according to ATP-III and IDF criteria.
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Prevalence of the metabolic syndrome per patient group Figure 1
Prevalence of the metabolic syndrome per patient group. 
First-episode patients: duration of illness <1.5 years; recent-
onset patients: duration of illness >1.5 years and <10 years; 
subchronic patients: duration of illness >10 years and <20 
years; chronic patients: duration of illness >20 years.
Glucose abnormalities per patient group Figure 2
Glucose abnormalities per patient group. First-episode 
patients: duration of illness <1.5 years; recent-onset patients: 
duration of illness >1.5 years and <10 years; subchronic 
patients: duration of illness >10 years and <20 years; chronic 
patients: duration of illness >20 years.Clinical Practice and Epidemiology in Mental Health 2006, 2:14 http://www.cpementalhealth.com/content/2/1/14
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from 1.6% in the 15–25 age-band to 19.2% in the 55–65
age-band. The prevalence of diabetes per age-band was 4
to 5 times higher in patients with schizophrenia.
4.2. Prevalence of metabolic abnormalities and its 
implications for clinical practice
The data confirm that metabolic abnormalities are highly
prevalent in a relatively young sample of schizophrenic
patients treated with antipsychotics. Two large scale natu-
ralistic studies in Belgium however revealed that the
screening and diagnosis of these abnormalities in patients
treated with antipsychotics still have not become routine
practice, and that therefore, these abnormalities fre-
quently remain untreated [40,41]. The data also suggest
that when these patients would have been screened
according to the current American Psychiatric Associa-
tion/American Diabetes Association guidelines, relying
only on fasting glucose, more than half of patients with
diabetes (14 out of 26 or 53.8%) would not have been
detected and thus, would not have been adequately
treated. This is in line with the findings of Adam and Tari-
gan [42], and underscores the need for a more thorough
screening in high-risk populations. Clearly, schizophrenic
patients treated with antipsychotics ought to be consid-
ered at high risk of developing diabetes [43], as is con-
firmed by the current data.
Although considered costly and inconvenient by some
[44,45], the use of OGTT's as a screening method for
patients diagnosed with schizophrenia should therefore
be encouraged, and certainly for very high risk patients
presenting with IFG [46,47] or MetS. Moreover, the cur-
rent data underscore the need for screening for metabolic
abnormalities in patients diagnosed with schizophrenia,
already starting from the onset of the illness, as suggested
in the literature [12,47-49].
4.3. Evolution over time: expression of vulnerability or 
iatrogenic effect?
The current data suggest a greater vulnerability to develop
metabolic abnormalities for patients diagnosed with
schizophrenia when compared to the general population.
A higher prevalence of metabolic abnormalities was
already present in the age-band between 15 and 25 years
old and increased with increasing age and duration of ill-
ness, which suggests a direct impact of the illness and/or
negative metabolic side-effects of antipsychotic medica-
tion. The suggestion of a direct impact of the illness of
schizophrenia and/or its pharmacological treatment on
the development of metabolic abnormalities is in line
with another Belgian study (BEST, i.e. "Belgian Evaluation
of Screening and Treatment of high risk patients based on
waist and age") [50]. This study was recently performed in
8,587 middle-aged (40–75 years) individuals without any
cardiovascular history, consecutively selected by general
practitioners upon a moderately increased waist circum-
ference (≥ 80 cm in women and ≥ 94 cm in men). In this
survey, 25 % of the non-diabetic population had the met-
abolic syndrome according to NCEP-ATP III criteria, thus
a much lower prevalence than the 36.7 % observed in the
subgroup of patients with the longest duration of the ill-
Table 5: Glucose abnormalities.
FE <10 yr 10 to 20 yr >20 yr p
All abnormalities 12% (12) 22.3% (29) 36.8% (37) 44.5% (43) 0.0001
IFG, IGT 9% (9) 20% (26) 30.2% (32) 38.0% (30)
Diabetes 3% (3) 2.3% (3) 6.6% (7) 16.5% (13)
Fasting abnormalities 8% (8) 16.9% (22) 27.3% (29) 40.5% (32) 0.0001
IFG 6% (6) 16.1% (21) 24.5% (26) 32.9% (26)
Diabetes 2% (2) 0.8% (1) 2.8% (3) 7.6% (6)
Abnormalities at 120 
min in OGTT
7% (7) 9.2% (12) 22.6% (24) 35.4% (28) 0.0001
IGT 6% (6) 6.9% (9) 17.9% (19) 24.0% (19)
Diabetes 1% (1) 2.3% (3) 4.7% (5) 11.4% (9)
Prevalence of diabetes per age-band in patients with schizo- phrenia compared to the general population Figure 4
Prevalence of diabetes per age-band in patients with schizo-
phrenia compared to the general population.
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ness. This difference is striking since the subjects of BEST
were older (61 vs 50 years) and had a much higher BMI
(31.8 vs 26.6 kg/m2) when compared to the patients with
chronic schizophrenia in our sample, obviously due to
selection criteria. Furthermore, in the subgroup with the
longest duration of illness, the prevalence of diabetes
(16.5%) was almost similar to that observed in the non-
psychiatric population of the BEST study (18%), despite a
10 year younger age and a 5 kg/m2 lower BMI. These find-
ings support a deleterious metabolic effect of the illness of
schizophrenia itself and/or antipsychotic medication.
Interestingly, the increase of the prevalence of the MetS
with age was similar to that of the general population,
meaning that although there was a higher prevalence of
the MetS in patients with schizophrenia, the difference in
prevalence with the general population remained more or
less stable. In contrast, the difference in the prevalence of
diabetes in patients with schizophrenia and the general
population dramatically and linearly increased from 1.6%
in the 15–25 age-band to 19.2% in the 55–65 age-band.
The interpretation of these findings is difficult and needs
to be done with caution, especially given the cross-sec-
tional nature of the current study. They seem to suggest
that the development of diabetes is not necessarily sec-
ondary to the development of MetS and that there could
be an inherent vulnerability to diabetes in patients with
schizophrenia, possibly aggravated by the metabolic side-
effects of (some) antipsychotic medications. The finding
that patients who were treated with clozapine were more
likely to develop diabetes compared to patients treated
with other antipsychotics is in line with this interpreta-
tion.
4.4. Methodological issues
This study also has some limitations. First and most
importantly, it is a cross-sectional study. Therefore, one
has to be cautious when interpreting the differences
between patient groups, since cohort effects could (in
part) explain the differences in the presence of metabolic
abnormalities between patient groups. However, cohort
effects are most likely to reduce differences between
patients to the null in the present study, as the prevalence
of diabetes and obesity has been rising rapidly in children,
adolescents and young adults worldwide [51,52]. Second,
this study was restricted to one site, indicating that the
interpretation of the results needs to be done with cau-
tion, since large regional differences in metabolic param-
eters have been reported in the literature [53] Third,
patients were not equally spread over the different age-
bands, with especially a low number of patients in the
oldest age-band (n = 20) which could have biased our
findings in this specific age-band. Fourth, insufficient
patients were included in the present study to allow a
dichotomization according to gender over the different
age-bands, although a significant influence of gender on
the occurrence of metabolic abnormalities was found in
Table 7: Abnormal lipid values.
FE <10 yr 10 to 20 yr >20 yr p
CHOL (≥ 190 mg/dl) 27% (27) 45.4% (59) 61.3% (65) 60.8% (48) 0.0001
TG (≥ 150 mg/dl) 33% (33) 36.1% (47) 50.9% (54) 46.8% (37) 0.0252
HDL (M<40 mg/dl; 
F<50 mg/dl)
26% (26) 27.7% (36) 31.1% (33) 31.6% (26) ns
LDL (≥ 115 mg/dl) 28% (28) 45.4% (59) 54.7% (58) 53.2% (42) 0.0005
CHOL/HDL (≥ 4) 30% (30) 42.3% (55) 53.8% (57) 49.4% (39) 0.0043
LDL/HDL (≥ 3) 14% (14) 23.1% (30) 33.0% (35) 32.9% (26) 0.0050
Table 6: Glucose abnormalities in relation to antipsychotic treatment.
Diabetes (n = 26) Prediabetes (n = 97) Normal values (n = 292)
Only FGA (n = 35) 8.6% (3) 25.7% (9) 65.7% (23)
Combination FGA + SGA (n = 45) 2.2% (1) 28.9% (13) 68.9% (31)
Combination SGA (n = 19) 5.3% (1) 21.0% (4) 73.7% (14)
Only 1 SGA (n = 314) 6.7% (21) 22.6% (71) 70.7% (222)
Amisulpride (n = 26) 0% (0) 3.9% (1) 96.1% (25)
Aripiprazole (n = 3) 0% (0) 0% (0) 100% (3)
Clozapine (n = 54) 9.3% (5) 42.6% (23) 48.1% (26)
Risperidone (n = 75) 6.6% (5) 22.7% (17) 70.7% (53)
Quetiapine (n = 44) 11.4% (5) 9.1% (4) 79.5% (35)
Olanzapine (n = 112) 5.4% (6) 23.2% (26) 71.4% (80)Clinical Practice and Epidemiology in Mental Health 2006, 2:14 http://www.cpementalhealth.com/content/2/1/14
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the present study and was also reported in the literature
[54, 55].
5. Conclusion
Metabolic abnormalities were already present in first-epi-
sode patients, but their prevalence considerably increased
with increasing duration of illness. When compared to the
general population matched for age and gender, higher
rates of the MetS and diabetes were observed for patients
with schizophrenia. For the MetS, the increase of the prev-
alence was similar to that of the general population. In
contrast, the difference in the prevalence of diabetes in
patients with schizophrenia and the general population
dramatically and linearly increased from 1.6% in the 15–
25 age-band to 19.2% in the 55–65 age-band. The preva-
lence of diabetes per age-band was 4 to 5 times higher in
patients with schizophrenia. Thus, the current data sug-
gest that on the one hand metabolic abnormalities are an
inherent part of schizophrenic illness, as they are already
present in first-episode patients. On the other hand, how-
ever, the current data suggest a direct effect of the illness
and/or antipsychotic medication on the development of
metabolic abnormalities, so that prevention strategies,
identification of risk factors, early detection through ade-
quate screening and treatment of metabolic abnormalities
could well be of eminent importance in these patients.
The current data underscore the need for screening for
MetS, diabetes and lipid abnormalities in patients diag-
nosed with schizophrenia, already starting from the onset
of the illness.
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